Skip to content
X

Cadent Therapeutics
Field: Neurological & psychiatric disorders
Stage: Phase II
Status: Private
CEO: Jodie Morrison
Cadent Therapeutics, currently undergoing acquisition by Novartis, is developing novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease. Currently in early clinical development, Cadent is rapidly advancing its pipeline of therapies to treat spinocerebellar ataxia, essential tremor and schizophrenia. Cadent’s subtype selective NMDA receptor negative allosteric modulation technology for the treatment of depression is licensed to Novartis.
Press Releases
-
22Dec
-
17Dec
-
30Apr
-
11Mar
-
17Feb
-
22Oct
-
30May
-
26May
-
18Nov
-
03Jul
-
13Mar
-
18Oct
2021
2020
2019
2018
2017